Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pharmaceutical rivals don’t often come to each other’s defense. But after the US Department of Health and Human Services ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers ...

CEO Albert Bourla has reportedly said that the company has made no commitments during its meeting with the Trump ...

Good morning. Pfizer’s Albert Bourla has become a fixture among Fortune 500 CEOs, having run the pharma giant since 2018. Yet Bourla—who trained as a veterinarian and joined Pfizer’s animal ...

54. It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...

Albert Bourla said Pfizer is being "frugal" with investments because of the uncertainty surrounding tariffs.

STORY: Pfizer CEO Albert Bourla said Monday that he and other drug companies met with the Trump administration to discuss ...

Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 8:00 AM ETCompany ParticipantsAlbert Bourla - Chairman of ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

In today’s CEO Daily: Diane Brady talks to Pfizer CEO Albert Bourla about defending science amid a backdrop of political threats. The big story: Trump’s tariff regime is open to compromises.